Clinical Trial

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2017-01-25; most recent amendment 2026-06-11.
Status change: Recruiting → Active, Not Recruiting 2023-07-21
Status change: Active, Not Recruiting → Recruiting 2020-08-04
Status change: Recruiting → Active, Not Recruiting 2020-04-01
Trial Details
NCT Number NCT03032406
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Breast Cancer Stage IIB
Enrollment 53 participants
Start Date 2017-01-23
Primary Completion 2022-05-17 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29